These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 7763202)
1. Randomized, double-blind, controlled trial of acetylcysteine in amyotrophic lateral sclerosis. Louwerse ES; Weverling GJ; Bossuyt PM; Meyjes FE; de Jong JM Arch Neurol; 1995 Jun; 52(6):559-64. PubMed ID: 7763202 [TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial. Ludolph AC; Schuster J; Dorst J; Dupuis L; Dreyhaupt J; Weishaupt JH; Kassubek J; Weiland U; Petri S; Meyer T; Grosskreutz J; Schrank B; Boentert M; Emmer A; Hermann A; Zeller D; Prudlo J; Winkler AS; Grehl T; Heneka MT; Wollebæk Johannesen S; Göricke B; Lancet Neurol; 2018 Aug; 17(8):681-688. PubMed ID: 29934198 [TBL] [Abstract][Full Text] [Related]
3. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. Bensimon G; Lacomblez L; Meininger V N Engl J Med; 1994 Mar; 330(9):585-91. PubMed ID: 8302340 [TBL] [Abstract][Full Text] [Related]
4. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Miller RG; Mitchell JD; Lyon M; Moore DH Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806 [TBL] [Abstract][Full Text] [Related]
5. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial. Cudkowicz ME; van den Berg LH; Shefner JM; Mitsumoto H; Mora JS; Ludolph A; Hardiman O; Bozik ME; Ingersoll EW; Archibald D; Meyers AL; Dong Y; Farwell WR; Kerr DA; Lancet Neurol; 2013 Nov; 12(11):1059-67. PubMed ID: 24067398 [TBL] [Abstract][Full Text] [Related]
6. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lacomblez L; Bensimon G; Leigh PN; Guillet P; Meininger V Lancet; 1996 May; 347(9013):1425-31. PubMed ID: 8676624 [TBL] [Abstract][Full Text] [Related]
7. A clinical trial of dextromethorphan in amyotrophic lateral sclerosis. Gredal O; Werdelin L; Bak S; Christensen PB; Boysen G; Kristensen MO; Jespersen JH; Regeur L; Hinge HH; Jensen TS Acta Neurol Scand; 1997 Jul; 96(1):8-13. PubMed ID: 9262126 [TBL] [Abstract][Full Text] [Related]
8. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Miller RG; Mitchell JD; Lyon M; Moore DH Cochrane Database Syst Rev; 2002; (2):CD001447. PubMed ID: 12076411 [TBL] [Abstract][Full Text] [Related]
9. Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial. ; Morrison KE; Dhariwal S; Hornabrook R; Savage L; Burn DJ; Khoo TK; Kelly J; Murphy CL; Al-Chalabi A; Dougherty A; Leigh PN; Wijesekera L; Thornhill M; Ellis CM; O'Hanlon K; Panicker J; Pate L; Ray P; Wyatt L; Young CA; Copeland L; Ealing J; Hamdalla H; Leroi I; Murphy C; O'Keeffe F; Oughton E; Partington L; Paterson P; Rog D; Sathish A; Sexton D; Smith J; Vanek H; Dodds S; Williams TL; Steen IN; Clarke J; Eziefula C; Howard R; Orrell R; Sidle K; Sylvester R; Barrett W; Merritt C; Talbot K; Turner MR; Whatley C; Williams C; Williams J; Cosby C; Hanemann CO; Iman I; Philips C; Timings L; Crawford SE; Hewamadduma C; Hibberd R; Hollinger H; McDermott C; Mils G; Rafiq M; Shaw PJ; Taylor A; Waines E; Walsh T; Addison-Jones R; Birt J; Hare M; Majid T Lancet Neurol; 2013 Apr; 12(4):339-45. PubMed ID: 23453347 [TBL] [Abstract][Full Text] [Related]
10. Long-term survival of participants in a phase II randomized trial of RNS60 in amyotrophic lateral sclerosis. Pupillo E; Bianchi E; Bonetto V; Pasetto L; Bendotti C; Paganoni S; Mandrioli J; Mazzini L; Brain Behav Immun; 2024 Nov; 122():456-462. PubMed ID: 39182589 [TBL] [Abstract][Full Text] [Related]
11. A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. ALS CNTF Treatment Study Group. Neurology; 1996 May; 46(5):1244-9. PubMed ID: 8628460 [TBL] [Abstract][Full Text] [Related]
12. A double-blind study of the effectiveness of cyclosporine in amyotrophic lateral sclerosis. Appel SH; Stewart SS; Appel V; Harati Y; Mietlowski W; Weiss W; Belendiuk GW Arch Neurol; 1988 Apr; 45(4):381-6. PubMed ID: 3281637 [TBL] [Abstract][Full Text] [Related]
13. High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study. Graf M; Ecker D; Horowski R; Kramer B; Riederer P; Gerlach M; Hager C; Ludolph AC; Becker G; Osterhage J; Jost WH; Schrank B; Stein C; Kostopulos P; Lubik S; Wekwerth K; Dengler R; Troeger M; Wuerz A; Hoge A; Schrader C; Schimke N; Krampfl K; Petri S; Zierz S; Eger K; Neudecker S; Traufeller K; Sievert M; Neundörfer B; Hecht M; J Neural Transm (Vienna); 2005 May; 112(5):649-60. PubMed ID: 15517433 [TBL] [Abstract][Full Text] [Related]
14. Mecasin treatment in patients with amyotrophic lateral sclerosis: study protocol for a randomized controlled trial. Kim S; Kim JK; Son MJ; Kim D; Song B; Son I; Kang HW; Lee J; Kim S Trials; 2018 Apr; 19(1):225. PubMed ID: 29653550 [TBL] [Abstract][Full Text] [Related]
15. Selegiline is ineffective in a collaborative double-blind, placebo-controlled trial for treatment of amyotrophic lateral sclerosis. Lange DJ; Murphy PL; Diamond B; Appel V; Lai EC; Younger DS; Appel SH Arch Neurol; 1998 Jan; 55(1):93-6. PubMed ID: 9443715 [TBL] [Abstract][Full Text] [Related]
16. A phase II-III trial of olesoxime in subjects with amyotrophic lateral sclerosis. Lenglet T; Lacomblez L; Abitbol JL; Ludolph A; Mora JS; Robberecht W; Shaw PJ; Pruss RM; Cuvier V; Meininger V; Eur J Neurol; 2014 Mar; 21(3):529-36. PubMed ID: 24447620 [TBL] [Abstract][Full Text] [Related]
17. Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double- blind, randomized, multicentre, placebo-controlled trial. Meininger V; Drory VE; Leigh PN; Ludolph A; Robberecht W; Silani V Amyotroph Lateral Scler; 2009; 10(5-6):378-83. PubMed ID: 19922128 [TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial. Meininger V; Genge A; van den Berg LH; Robberecht W; Ludolph A; Chio A; Kim SH; Leigh PN; Kiernan MC; Shefner JM; Desnuelle C; Morrison KE; Petri S; Boswell D; Temple J; Mohindra R; Davies M; Bullman J; Rees P; Lavrov A; Lancet Neurol; 2017 Mar; 16(3):208-216. PubMed ID: 28139349 [TBL] [Abstract][Full Text] [Related]
19. A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. Cudkowicz ME; Shefner JM; Schoenfeld DA; Brown RH; Johnson H; Qureshi M; Jacobs M; Rothstein JD; Appel SH; Pascuzzi RM; Heiman-Patterson TD; Donofrio PD; David WS; Russell JA; Tandan R; Pioro EP; Felice KJ; Rosenfeld J; Mandler RN; Sachs GM; Bradley WG; Raynor EM; Baquis GD; Belsh JM; Novella S; Goldstein J; Hulihan J; Neurology; 2003 Aug; 61(4):456-64. PubMed ID: 12939417 [TBL] [Abstract][Full Text] [Related]
20. A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Groeneveld GJ; Veldink JH; van der Tweel I; Kalmijn S; Beijer C; de Visser M; Wokke JH; Franssen H; van den Berg LH Ann Neurol; 2003 Apr; 53(4):437-45. PubMed ID: 12666111 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]